The In Vivo Pharmacokinetics of Block Copolymers Containing Polyethylene Glycol Used in Nanocarrier Drug Delivery Systems

Abstract

Polyethylene glycol (PEG) is one of the most commonly used synthetic macromolecular polymers for modifying small molecule drugs, peptides, proteins, or nanodrug delivery systems to improve their water solubility, biocompatibility, and stability. Block copolymers containing PEG have been widely used in nanodrug delivery systems such as solid lipid nanoparticles, polymeric nanoparticles, polymeric micelles, and liposomes. To date, although numerous PEGylated nanodrug delivery systems have been developed, only a few have been approved for clinical application. Poor safety and effectivity are important reasons for the high failure rate of nanodrug delivery system clinical trials. These factors are not only related to the loaded drugs and released drugs but are also related to the nanocarriers. Therefore, investigating the in vivo spatiotemporal fate of block copolymers containing PEG used in nanodrug delivery systems is necessary and important for evaluating their safety, efficacy, and toxicity. In this article, we will review the information that has been reported about the absorption, distribution, metabolism, and excretion of block copolymers containing PEG. We believe this review is helpful to understand the biologic fate of block copolymers containing PEG.This review describes pharmacokinetic study of block copolymers containing polyethylene glycol. The main focus of this paper is the in vivo fate of these polyethylene glycol-related copolymers after their release from nanocarriers. This review is helpful for understanding of the in vivo fate of block copolymers containing polyethylene glycol used in nanocarrier drug delivery systems.